Fagron NV Asset Resilience Ratio
Fagron NV asset resilience ratio. Fagron NV (FAGR) has an Asset Resilience Ratio of 0.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Fagron NV balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Fagron NV (2015–2025)
Asset resilience ratio of Fagron NV from 2015 to 2025. This chart shows how Fagron NV's Asset Resilience Ratio has changed over time. See FAGR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Fagron NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Fagron NV asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €93.00K | 0.01% |
| Total Liquid Assets | €93.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Fagron NV maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Fagron NV Industry Peers by Asset Resilience Ratio
Compare Fagron NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Fagron NV Asset Resilience Ratio by Year (2015–2025)
Fagron NV asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Fagron NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €11.00K ≈ $12.86K |
€1.24 Billion ≈ $1.45 Billion |
-0.08pp |
| 2024-12-31 | 0.08% | €886.00K ≈ $1.04 Million |
€1.08 Billion ≈ $1.27 Billion |
-0.34pp |
| 2023-12-31 | 0.42% | €4.27 Million ≈ $4.99 Million |
€1.01 Billion ≈ $1.18 Billion |
+0.38pp |
| 2022-12-31 | 0.05% | €451.00K ≈ $527.27K |
€971.01 Million ≈ $1.14 Billion |
+0.21pp |
| 2021-12-31 | -0.16% | €-1.32 Million ≈ $-1.54 Million |
€800.42 Million ≈ $935.78 Million |
-0.05pp |
| 2020-12-31 | -0.11% | €-862.00K ≈ $-1.01 Million |
€752.83 Million ≈ $880.13 Million |
+0.14pp |
| 2019-12-31 | -0.26% | €-2.07 Million ≈ $-2.42 Million |
€801.24 Million ≈ $936.73 Million |
-0.45pp |
| 2018-12-31 | 0.19% | €1.29 Million ≈ $1.51 Million |
€682.77 Million ≈ $798.23 Million |
+0.22pp |
| 2017-12-31 | -0.03% | €-163.00K ≈ $-190.56K |
€594.05 Million ≈ $694.50 Million |
-0.12pp |
| 2016-12-31 | 0.09% | €816.00K ≈ $953.99K |
€868.05 Million ≈ $1.01 Billion |
+0.72pp |
| 2015-12-31 | -0.63% | €-4.32 Million ≈ $-5.05 Million |
€689.38 Million ≈ $805.96 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more